As the new year begins, several developments in heart health research are making the news.
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout
ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose
Your daily dose of the clinical news you may have missed.
Long COVID's Long Road: A Year 5 Update with Noah Greenspan DPT, PT, CCS, EMT-B
Five years after the COVID-19 pandemic was declared, the protean syndrome dubbed long COVID continues to affect millions; Greenspan is dedicated to helping.